EA039310B1 - Способы снижения сердечно-сосудистого риска - Google Patents
Способы снижения сердечно-сосудистого риска Download PDFInfo
- Publication number
- EA039310B1 EA039310B1 EA201691847A EA201691847A EA039310B1 EA 039310 B1 EA039310 B1 EA 039310B1 EA 201691847 A EA201691847 A EA 201691847A EA 201691847 A EA201691847 A EA 201691847A EA 039310 B1 EA039310 B1 EA 039310B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- patient
- antibody
- dose
- antigen
- patients
- Prior art date
Links
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 94
- 238000000034 method Methods 0.000 title claims abstract description 90
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims abstract description 94
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 61
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims abstract description 41
- 102000004895 Lipoproteins Human genes 0.000 claims abstract description 40
- 108090001030 Lipoproteins Proteins 0.000 claims abstract description 40
- 231100000682 maximum tolerated dose Toxicity 0.000 claims abstract description 32
- 230000000923 atherogenic effect Effects 0.000 claims abstract description 29
- 238000011282 treatment Methods 0.000 claims description 95
- 239000000427 antigen Substances 0.000 claims description 80
- 102000036639 antigens Human genes 0.000 claims description 80
- 108091007433 antigens Proteins 0.000 claims description 80
- 230000027455 binding Effects 0.000 claims description 77
- 208000029078 coronary artery disease Diseases 0.000 claims description 68
- 108010028554 LDL Cholesterol Proteins 0.000 claims description 67
- 239000012634 fragment Substances 0.000 claims description 60
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 46
- 101710180553 Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 claims description 37
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 claims description 37
- 230000034994 death Effects 0.000 claims description 37
- 231100000517 death Toxicity 0.000 claims description 37
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 35
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 32
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims description 25
- 208000010125 myocardial infarction Diseases 0.000 claims description 25
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 22
- 230000000250 revascularization Effects 0.000 claims description 22
- 208000007814 Unstable Angina Diseases 0.000 claims description 20
- 206010002388 Angina unstable Diseases 0.000 claims description 19
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 19
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 19
- 229960005370 atorvastatin Drugs 0.000 claims description 19
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 19
- 229960000672 rosuvastatin Drugs 0.000 claims description 19
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims description 19
- 108010023302 HDL Cholesterol Proteins 0.000 claims description 17
- 230000001771 impaired effect Effects 0.000 claims description 16
- 210000002966 serum Anatomy 0.000 claims description 14
- 208000028867 ischemia Diseases 0.000 claims description 13
- 206010000891 acute myocardial infarction Diseases 0.000 claims description 11
- 101710095342 Apolipoprotein B Proteins 0.000 claims description 10
- 102100040202 Apolipoprotein B-100 Human genes 0.000 claims description 10
- 230000000414 obstructive effect Effects 0.000 claims description 10
- 208000024891 symptom Diseases 0.000 claims description 9
- 238000005259 measurement Methods 0.000 claims description 8
- 208000031225 myocardial ischemia Diseases 0.000 claims description 7
- 206010061216 Infarction Diseases 0.000 claims description 6
- 108010007622 LDL Lipoproteins Proteins 0.000 claims description 6
- 102000007330 LDL Lipoproteins Human genes 0.000 claims description 6
- 230000000747 cardiac effect Effects 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 230000007574 infarction Effects 0.000 claims description 6
- 201000000057 Coronary Stenosis Diseases 0.000 claims description 5
- 238000002583 angiography Methods 0.000 claims description 5
- 239000000090 biomarker Substances 0.000 claims description 5
- 230000033001 locomotion Effects 0.000 claims description 5
- 230000010412 perfusion Effects 0.000 claims description 5
- 208000012902 Nervous system disease Diseases 0.000 claims description 4
- 230000005856 abnormality Effects 0.000 claims description 4
- 208000020832 chronic kidney disease Diseases 0.000 claims description 4
- 230000000302 ischemic effect Effects 0.000 claims description 4
- 230000000284 resting effect Effects 0.000 claims description 4
- 238000012800 visualization Methods 0.000 claims description 3
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 229960004539 alirocumab Drugs 0.000 abstract description 103
- 229940122392 PCSK9 inhibitor Drugs 0.000 abstract description 48
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract description 21
- 150000002632 lipids Chemical class 0.000 abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 19
- 208000037765 diseases and disorders Diseases 0.000 abstract description 2
- 239000000902 placebo Substances 0.000 description 77
- 229940068196 placebo Drugs 0.000 description 77
- 238000004458 analytical method Methods 0.000 description 42
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 39
- 210000004602 germ cell Anatomy 0.000 description 24
- 238000012360 testing method Methods 0.000 description 23
- 239000003814 drug Substances 0.000 description 21
- 238000002347 injection Methods 0.000 description 19
- 239000007924 injection Substances 0.000 description 19
- 230000007211 cardiovascular event Effects 0.000 description 18
- 230000009467 reduction Effects 0.000 description 18
- 230000002411 adverse Effects 0.000 description 17
- 235000012000 cholesterol Nutrition 0.000 description 16
- 230000007774 longterm Effects 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 14
- 238000008214 LDL Cholesterol Methods 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 238000006467 substitution reaction Methods 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 235000009421 Myristica fragrans Nutrition 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- 239000001115 mace Substances 0.000 description 11
- 238000011269 treatment regimen Methods 0.000 description 11
- 229940024606 amino acid Drugs 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- 230000035772 mutation Effects 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 238000012216 screening Methods 0.000 description 9
- 208000024172 Cardiovascular disease Diseases 0.000 description 8
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 8
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 229960002855 simvastatin Drugs 0.000 description 8
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 8
- 150000003626 triacylglycerols Chemical class 0.000 description 8
- 206010019280 Heart failures Diseases 0.000 description 7
- 208000006011 Stroke Diseases 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 7
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 7
- 229960002297 fenofibrate Drugs 0.000 description 7
- 238000009533 lab test Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 102100040214 Apolipoprotein(a) Human genes 0.000 description 6
- 101710115418 Apolipoprotein(a) Proteins 0.000 description 6
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000006735 deficit Effects 0.000 description 6
- 230000007717 exclusion Effects 0.000 description 6
- 229960000815 ezetimibe Drugs 0.000 description 6
- 102000053786 human PCSK9 Human genes 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 206010007559 Cardiac failure congestive Diseases 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 5
- 108010044159 Proprotein Convertases Proteins 0.000 description 5
- 102000006437 Proprotein Convertases Human genes 0.000 description 5
- 108090000787 Subtilisin Proteins 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000013270 controlled release Methods 0.000 description 5
- -1 fibrates Substances 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 229940126602 investigational medicinal product Drugs 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 108010074051 C-Reactive Protein Proteins 0.000 description 4
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 4
- 229940093817 Convertase inhibitor Drugs 0.000 description 4
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 4
- 102000004420 Creatine Kinase Human genes 0.000 description 4
- 108010042126 Creatine kinase Proteins 0.000 description 4
- 206010022095 Injection Site reaction Diseases 0.000 description 4
- 101710172072 Kexin Proteins 0.000 description 4
- 230000003143 atherosclerotic effect Effects 0.000 description 4
- 238000004820 blood count Methods 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 4
- 229960000258 corticotropin Drugs 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 229940125753 fibrate Drugs 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229960003512 nicotinic acid Drugs 0.000 description 4
- 235000001968 nicotinic acid Nutrition 0.000 description 4
- 239000011664 nicotinic acid Substances 0.000 description 4
- 231100001160 nonlethal Toxicity 0.000 description 4
- 239000002417 nutraceutical Substances 0.000 description 4
- 235000021436 nutraceutical agent Nutrition 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- 238000009597 pregnancy test Methods 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 3
- 208000000112 Myalgia Diseases 0.000 description 3
- 229940127355 PCSK9 Inhibitors Drugs 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010048214 Xanthoma Diseases 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 229940090047 auto-injector Drugs 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 201000001386 familial hypercholesterolemia Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 208000007475 hemolytic anemia Diseases 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 3
- 230000002045 lasting effect Effects 0.000 description 3
- 210000002414 leg Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 3
- 229940012843 omega-3 fatty acid Drugs 0.000 description 3
- 239000006014 omega-3 oil Substances 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000002562 urinalysis Methods 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 2
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- 206010049993 Cardiac death Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 206010011906 Death Diseases 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 206010022562 Intermittent claudication Diseases 0.000 description 2
- 108010001831 LDL receptors Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 2
- 208000032109 Transient ischaemic attack Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229940087168 alpha tocopherol Drugs 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 210000000270 basal cell Anatomy 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 229940124301 concurrent medication Drugs 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000003163 gonadal steroid hormone Substances 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 208000021156 intermittent vascular claudication Diseases 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 208000037906 ischaemic injury Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- ORMNNUPLFAPCFD-DVLYDCSHSA-M phenethicillin potassium Chemical compound [K+].N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C(C)OC1=CC=CC=C1 ORMNNUPLFAPCFD-DVLYDCSHSA-M 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 229940103121 simvastatin 80 mg Drugs 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 201000010875 transient cerebral ischemia Diseases 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- IXRAQYMAEVFORF-UTLNTRLCSA-N (3S,8S,9S,10R,13S,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,16-diol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(O)[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 IXRAQYMAEVFORF-UTLNTRLCSA-N 0.000 description 1
- XUKUURHRXDUEBC-SVBPBHIXSA-N (3s,5s)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@H](O)C[C@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-SVBPBHIXSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- VTAKZNRDSPNOAU-UHFFFAOYSA-M 2-(chloromethyl)oxirane;hydron;prop-2-en-1-amine;n-prop-2-enyldecan-1-amine;trimethyl-[6-(prop-2-enylamino)hexyl]azanium;dichloride Chemical compound Cl.[Cl-].NCC=C.ClCC1CO1.CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C VTAKZNRDSPNOAU-UHFFFAOYSA-M 0.000 description 1
- YZQLWPMZQVHJED-UHFFFAOYSA-N 2-methylpropanethioic acid S-[2-[[[1-(2-ethylbutyl)cyclohexyl]-oxomethyl]amino]phenyl] ester Chemical compound C=1C=CC=C(SC(=O)C(C)C)C=1NC(=O)C1(CC(CC)CC)CCCCC1 YZQLWPMZQVHJED-UHFFFAOYSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 208000020576 Adrenal disease Diseases 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010027006 Apolipoproteins B Proteins 0.000 description 1
- 102000018616 Apolipoproteins B Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010006580 Bundle branch block left Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000018152 Cerebral disease Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 229920002905 Colesevelam Polymers 0.000 description 1
- 229920002911 Colestipol Polymers 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 102100030797 Conserved oligomeric Golgi complex subunit 2 Human genes 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 206010014476 Elevated cholesterol Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010019013 Haemorrhagic infarction Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000920113 Homo sapiens Conserved oligomeric Golgi complex subunit 2 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 206010027525 Microalbuminuria Diseases 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000029027 Musculoskeletal and connective tissue disease Diseases 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 240000001090 Papaver somniferum Species 0.000 description 1
- 235000008753 Papaver somniferum Nutrition 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 206010034576 Peripheral ischaemia Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000014993 Pituitary disease Diseases 0.000 description 1
- 244000134552 Plantago ovata Species 0.000 description 1
- 235000003421 Plantago ovata Nutrition 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 208000023146 Pre-existing disease Diseases 0.000 description 1
- 239000009223 Psyllium Substances 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 208000032327 Respiratory, thoracic and mediastinal disease Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 102000025171 antigen binding proteins Human genes 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 229920000080 bile acid sequestrant Polymers 0.000 description 1
- 229940096699 bile acid sequestrants Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 238000007705 chemical test Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 229960001152 colesevelam Drugs 0.000 description 1
- 229960002604 colestipol Drugs 0.000 description 1
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 1
- 230000004456 color vision Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002586 coronary angiography Methods 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 229950004181 dalcetrapib Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011257 definitive treatment Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000007435 diagnostic evaluation Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000011977 dual antiplatelet therapy Methods 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 229940015979 epipen Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229960000701 fenofibric acid Drugs 0.000 description 1
- MQOBSOSZFYZQOK-UHFFFAOYSA-N fenofibric acid Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C(=O)C1=CC=C(Cl)C=C1 MQOBSOSZFYZQOK-UHFFFAOYSA-N 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 229940062714 humalog mix Drugs 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000024615 inherited lipid metabolism disease Diseases 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000009592 kidney function test Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 238000010984 neurological examination Methods 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011422 pharmacological therapy Methods 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 208000017402 pituitary gland disease Diseases 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 238000011240 pooled analysis Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 229940070687 psyllium Drugs 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 238000012950 reanalysis Methods 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 230000004283 retinal dysfunction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000009863 secondary prevention Effects 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000032422 susceptibility to 5 coronary heart disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15305293 | 2015-02-26 | ||
| PCT/US2015/020564 WO2015142668A1 (en) | 2014-03-17 | 2015-03-13 | Methods for reducing cardiovascular risk |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201691847A1 EA201691847A1 (ru) | 2017-01-30 |
| EA039310B1 true EA039310B1 (ru) | 2022-01-12 |
Family
ID=52648962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201691847A EA039310B1 (ru) | 2015-02-26 | 2015-03-13 | Способы снижения сердечно-сосудистого риска |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20150284473A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3119810B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2017509624A (cg-RX-API-DMAC7.html) |
| KR (3) | KR20220157516A (cg-RX-API-DMAC7.html) |
| CN (3) | CN106794244A (cg-RX-API-DMAC7.html) |
| AU (3) | AU2015231713B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2942549A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA039310B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2978990T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE066839T2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL304491A (cg-RX-API-DMAC7.html) |
| MX (1) | MX380767B (cg-RX-API-DMAC7.html) |
| PL (1) | PL3119810T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015142668A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| CA3129996C (en) | 2009-06-15 | 2025-09-02 | Amarin Pharmaceuticals Ireland Limited | COMPOSITIONS AND METHODS FOR LOWERING TRIGLYCERIDES WITHOUT RAISED LDL-C LEVELS IN A SUBJECT UNDERGOING CONCOMITANT STATIN THERAPY |
| AR084938A1 (es) | 2011-01-28 | 2013-07-10 | Sanofi Sa | Anticuerpos humanos contra la proproteina convertasa subtilisina/kexina tipo 9 (anti pcsk9) para usar en metodos para tratar grupos de pacientes |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| ES2773111T3 (es) | 2011-09-16 | 2020-07-09 | Regeneron Pharma | Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a) |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| TW201534324A (zh) | 2013-06-07 | 2015-09-16 | Sanofi Sa | 藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法 |
| CN106062003A (zh) | 2013-11-12 | 2016-10-26 | 赛诺菲生物技术公司 | 用于与pcsk9抑制剂一起使用的给药方案 |
| AU2015289874A1 (en) * | 2014-07-14 | 2017-02-02 | Amgen Inc. | Crystalline antibody formulations |
| EP3753575A1 (en) * | 2014-07-16 | 2020-12-23 | Sanofi Biotechnology | Methods for treating high cardiovascular risk patients with hypercholesterolemia using inhibitors of pcsk9 |
| KR20240017117A (ko) | 2014-07-16 | 2024-02-06 | 사노피 바이오테크놀로지 | 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법 |
| WO2016046684A1 (en) | 2014-09-23 | 2016-03-31 | Pfizer Inc. | Treatment with anti-pcsk9 antibodies |
| EA201890519A1 (ru) | 2015-08-18 | 2018-07-31 | Ридженерон Фармасьютикалз, Инк. | Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов |
| JOP20190112A1 (ar) * | 2016-11-14 | 2019-05-14 | Amgen Inc | علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي |
| US10329620B2 (en) | 2017-01-12 | 2019-06-25 | Cardioforecast Ltd. | Methods and kits for treating cardiovascular disease |
| BR112019020148A2 (pt) | 2017-04-13 | 2020-05-05 | Cadila Healthcare Ltd | peptídeo |
| TW202521589A (zh) * | 2018-03-06 | 2025-06-01 | 法商賽諾菲生物技術公司 | 降低心血管風險的方法 |
| JP7513533B2 (ja) * | 2018-07-02 | 2024-07-09 | アブセントラ，エルエルシー | リポタンパク質ａの形成を減少させるための組成物及び方法、ならびに大動脈弁硬化症及び大動脈弁狭窄症の治療 |
| TN2021000028A1 (en) * | 2018-08-17 | 2022-10-03 | Amarin Pharmaceuticals Ie Ltd | Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject |
| DK4056176T3 (da) | 2018-09-24 | 2024-05-06 | Amarin Pharmaceuticals Ie Ltd | Fremgangsmåde til at reducere risikoen af kardiovaskulære hændelser hos et individ |
| US11248001B2 (en) | 2019-01-18 | 2022-02-15 | Astrazeneca Ab | PCSK9 inhibitors and methods of use thereof |
| CA3192235A1 (en) * | 2019-11-07 | 2021-05-14 | Medimmune, Llc | Endothelial lipase antibodies for the treatment of cardiovascular diseases |
| WO2021097120A1 (en) | 2019-11-12 | 2021-05-20 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter |
| US20230312750A1 (en) * | 2019-11-18 | 2023-10-05 | Ad Pharmaceuticals Co., Ltd. | Anti-pcsk9 antibody and use thereof |
| KR20240012390A (ko) | 2021-04-21 | 2024-01-29 | 애머린 파마슈티칼스 아일랜드 리미티드 | 심부전의 위험을 감소시키는 방법 |
| CN114848849B (zh) * | 2022-04-25 | 2023-11-17 | 南方科技大学 | Pcsk9蛋白抑制剂在治疗心血管疾病中的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010077854A1 (en) * | 2008-12-15 | 2010-07-08 | Regeneron Pharamaceuticals, Inc. | High affinity human antibodies to pcsk9 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| AR084938A1 (es) * | 2011-01-28 | 2013-07-10 | Sanofi Sa | Anticuerpos humanos contra la proproteina convertasa subtilisina/kexina tipo 9 (anti pcsk9) para usar en metodos para tratar grupos de pacientes |
| JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
-
2015
- 2015-03-13 CA CA2942549A patent/CA2942549A1/en active Pending
- 2015-03-13 EP EP15712241.7A patent/EP3119810B1/en active Active
- 2015-03-13 AU AU2015231713A patent/AU2015231713B2/en active Active
- 2015-03-13 PL PL15712241.7T patent/PL3119810T3/pl unknown
- 2015-03-13 WO PCT/US2015/020564 patent/WO2015142668A1/en not_active Ceased
- 2015-03-13 ES ES15712241T patent/ES2978990T3/es active Active
- 2015-03-13 JP JP2016556709A patent/JP2017509624A/ja active Pending
- 2015-03-13 KR KR1020227039740A patent/KR20220157516A/ko not_active Ceased
- 2015-03-13 EA EA201691847A patent/EA039310B1/ru unknown
- 2015-03-13 KR KR1020247040556A patent/KR20250006995A/ko active Pending
- 2015-03-13 CN CN201580024259.2A patent/CN106794244A/zh active Pending
- 2015-03-13 CN CN202210141133.5A patent/CN114558129A/zh active Pending
- 2015-03-13 KR KR1020167028383A patent/KR20160132459A/ko not_active Ceased
- 2015-03-13 MX MX2016011975A patent/MX380767B/es unknown
- 2015-03-13 US US14/657,192 patent/US20150284473A1/en not_active Abandoned
- 2015-03-13 HU HUE15712241A patent/HUE066839T2/hu unknown
- 2015-03-13 CN CN202210141115.7A patent/CN114642661A/zh active Pending
- 2015-03-13 EP EP24160083.2A patent/EP4403213A3/en active Pending
-
2021
- 2021-02-19 AU AU2021201118A patent/AU2021201118A1/en not_active Abandoned
- 2021-10-19 US US17/504,921 patent/US20220144969A1/en not_active Abandoned
-
2022
- 2022-07-22 JP JP2022116854A patent/JP2022141868A/ja active Pending
-
2023
- 2023-07-16 IL IL304491A patent/IL304491A/en unknown
-
2024
- 2024-07-19 JP JP2024115429A patent/JP2024147744A/ja active Pending
- 2024-07-31 AU AU2024205254A patent/AU2024205254A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010077854A1 (en) * | 2008-12-15 | 2010-07-08 | Regeneron Pharamaceuticals, Inc. | High affinity human antibodies to pcsk9 |
Non-Patent Citations (5)
| Title |
|---|
| Anonymous: "NCT01507831 on 2013_06_27: ClinicalTrials.gov Archive", 27 June 2013 (2013-06-27), XP055189981, Retrieved from the Internet: URL: https://clinicaltrials.gov/archive/NCT01507831/2013_06_27 [retrieved on 2015-05-19], brief summary; brief title; arm/group * |
| Anonymous: "NCT01663402 on 2014_03_11: ClinicalTrials.gov Archive", 11 March 2014 (2014-03-11), XP55189973, Retrieved from the Internet: URL: https://clinicaltrials.gov/archive/NCT01663402/2014_03_11 [retrieved on 2015-05-19], brief summary; brief title * |
| EVAN A. STEIN, GARY D. SWERGOLD: "Potential of Proprotein Convertase Subtilisin/Kexin Type 9 Based Therapeutics", CURRENT ATHEROSCLEROSIS REPORTS, SPRINGER US, NEW YORK, vol. 15, no. 3, 1 March 2013 (2013-03-01), New York, pages 1 - 14, XP055139364, ISSN: 1523-3804, DOI: 10.1007/s11883-013-0310-3 * |
| GREGORY G. SCHWARTZ, LAURENCE BESSAC, LISA G. BERDAN, DEEPAK L. BHATT, VERA BITTNER, RAFAEL DIAZ, SHAUN G. GOODMAN, CORINNE HANOTI: "Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial", AMERICAN HEART JOURNAL, ELSEVIER, AMSTERDAM, NL, vol. 168, no. 5, 1 November 2014 (2014-11-01), AMSTERDAM, NL , pages 682 - 689, XP002739740, ISSN: 0002-8703, DOI: 10.1016/j.ahj.2014.07.028 * |
| JAMES M. MCKENNEY, MICHAEL J. KOREN, DEAN J. KEREIAKES, CORINNE HANOTIN, ANNE-CATHERINE FERRAND, EVAN A. STEIN: "Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER, vol. 59, no. 25, 1 June 2012 (2012-06-01), pages 2344 - 2353, XP055049859, ISSN: 07351097, DOI: 10.1016/j.jacc.2012.03.007 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20250006995A (ko) | 2025-01-13 |
| AU2021201118A1 (en) | 2021-03-11 |
| ES2978990T3 (es) | 2024-09-23 |
| AU2015231713B2 (en) | 2020-11-19 |
| JP2024147744A (ja) | 2024-10-16 |
| JP2017509624A (ja) | 2017-04-06 |
| KR20160132459A (ko) | 2016-11-18 |
| KR20220157516A (ko) | 2022-11-29 |
| EP4403213A2 (en) | 2024-07-24 |
| US20220144969A1 (en) | 2022-05-12 |
| EP3119810B1 (en) | 2024-02-28 |
| EP3119810A1 (en) | 2017-01-25 |
| EA201691847A1 (ru) | 2017-01-30 |
| EP4403213A3 (en) | 2024-10-23 |
| JP2022141868A (ja) | 2022-09-29 |
| CA2942549A1 (en) | 2015-09-24 |
| PL3119810T3 (pl) | 2024-07-15 |
| AU2024205254A1 (en) | 2024-10-03 |
| CN106794244A (zh) | 2017-05-31 |
| EP3119810C0 (en) | 2024-02-28 |
| IL304491A (en) | 2023-09-01 |
| US20150284473A1 (en) | 2015-10-08 |
| CN114558129A (zh) | 2022-05-31 |
| HUE066839T2 (hu) | 2024-09-28 |
| WO2015142668A1 (en) | 2015-09-24 |
| CN114642661A (zh) | 2022-06-21 |
| AU2015231713A1 (en) | 2016-10-20 |
| MX380767B (es) | 2025-03-12 |
| MX2016011975A (es) | 2016-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220144969A1 (en) | Methods for reducing cardiovascular risk | |
| US20250059300A1 (en) | METHODS FOR TREATING PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (heFH) WITH AN ANTI-PCSK9 ANTIBODY | |
| US20200255544A1 (en) | Methods for treating high cardiovascular risk patients with hypercholesterolemia | |
| EP3337828B1 (en) | Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis | |
| JP2020143156A (ja) | 心血管リスクを低減させる方法 | |
| HK40114248A (en) | Methods for reducing cardiovascular risk | |
| HK1232890A1 (en) | Methods for reducing cardiovascular risk | |
| HK1232890B (en) | Methods for reducing cardiovascular risk | |
| HK1236135B (en) | Methods for treating high cardiovascular risk patients with hypercholesterolemia | |
| HK1236135A1 (en) | Methods for treating high cardiovascular risk patients with hypercholesterolemia | |
| HK1255470B (en) | Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis | |
| EA041556B1 (ru) | Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией подвергающихся аферезу липопротеинов |